Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report
{{output}}
Immune checkpoint inhibitors, such as atezolizumab, have become integral to the treatment of various malignancies and have significantly improved clinical outcomes by enhancing host antitumor immune responses. However, with their expanding clinical use, immune... ...
